Very-low-density lipoprotein (VLDL)-producing and hepatitis C virus-replicating HepG2 cells secrete no more lipoviroparticles than VLDL-deficient Huh7.5 cells

Journal of Virology

Volumn 87, Issue 9, 2013, Pages 5065-5080

  Jammart, Baptiste ^a   Michelet, Maud ^a   Pécheur, Eve Isabelle ^a   Parent, Romain ^a   Bartosch, Birke ^a,b   Zoulim, Fabien ^a,b   Durantel, David ^a  

^a CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^b HOSPICES CIVILS DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN B ANTIBODY; APOLIPOPROTEIN E; CD81 ANTIGEN; DIMETHYL SULFOXIDE; DOUBLE STRANDED RNA; GLYCOPROTEIN E2; LIPOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NONSTRUCTURAL PROTEIN 5A; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; VIRUS PROTEIN; VIRUS RNA;

ARTICLE; CELL CULTURE; CELL STRAIN HEPG2; CELL STRAIN HUH7.5; CONTROLLED STUDY; ENZYME INHIBITION; HEPATITIS C VIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN SECRETION; RNA REPLICATION; VIRION; VIRUS PARTICLE; VIRUS REPLICATION;

CELL LINE, TUMOR; HEP G2 CELLS; HEPACIVIRUS; HEPATITIS C; HUMANS; LIPOPROTEINS, VLDL; VIRION; VIRUS ASSEMBLY; VIRUS RELEASE; VIRUS REPLICATION;

HEPATITIS C VIRUS;

EID: 84876311726     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01405-12     Document Type: Article

References (85)

1. Knobler H, Zhornicky T, Sandler A, Haran N, Ashur Y, Schattner A. 2003. Tumor necrosis factor-alpha-induced insulin resistance may mediate the hepatitis C virus-diabetes association. Am. J. Gastroenterol. 98: 2751-2756.
2. Moucari R, Asselah T, Cazals-Hatem D, Voitot H, Boyer N, Ripault M.-P, Sobesky R, Martinot-Peignoux M, Maylin S, Nicolas-Chanoine M.-H, Paradis V, Vidaud M, Valla D, Bedossa P, Marcellin P. 2008. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 134:416- 423.
3. Mason AL, Lau JY, Hoang N, Qian K, Alexander GJ, Xu L, Guo L, Jacob S, Regenstein FG, Zimmerman R, Everhart JE, Wasserfall C, Maclaren NK, Perrillo RP. 1999. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 29:328 -333.
4. Serfaty L, Capeau J. 2009. Hepatitis C, insulin resistance and diabetes: clinical and pathogenic data. Liver Int. 29(Suppl 2):13-25.
5. Asselah T, Rubbia-Brandt L, Marcellin P, Negro F. 2006. Steatosis in chronic hepatitis C: why does it really matter? Gut 55:123-130.
6. Negro F. 2010. Abnormalities of lipid metabolism in hepatitis C virus infection. Gut 59:1279 -1287.
7. Negro F, Sanyal AJ. 2009. Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data. Liver Int. 29(Suppl 2):26 -37.
8. Petit JM, Benichou M, Duvillard L, Jooste V, Bour JB, Minello A, Verges B, Brun JM, Gambert P, Hillon P. 2003. Hepatitis C virusassociated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis. Am. J. Gastroenterol. 98:1150 -1154.
9. Serfaty L, Andreani T, Giral P, Carbonell N, Chazouillères O, Poupon R. 2001. Hepatitis C virus induced hypobetalipoproteinemia: a possibl mechanism for steatosis in chronic hepatitis C. J. Hepatol. 34:428-434.
10. Dai C.-Y, Chuang W.-L, Ho C.-K, Hsieh M.-Y, Huang J.-F, Lee L.-P, Hou N.-J, Lin Z.-Y, Chen S.-C, Hsieh M.-Y, Wang L.-Y, Tsai J.-F, Chang W.-Y, Yu M.-L. 2008. Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: a community-based study. J. Hepatol. 49:9 -16.
11. Corey KE, Kane E, Munroe C, Barlow LL, Zheng H, Chung RT. 2009. Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. Hepatology 50:1030 -1037.
12. Adinolfi LE, Restivo L, Zampino R, Guerrera B, Lonardo A, Ruggiero L, Riello F, Loria P, Florio A. 2012. Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis. Atherosclerosis 221:496 -502.
13. Lerat H, Kammoun HL, Hainault I, Mérour E, Higgs MR, Callens C, Lemon SM, Foufelle F, Pawlotsky J.-M. 2009. Hepatitis C virus proteins induce lipogenesis and defective triglyceride secretion in transgenic mice. J. Biol. Chem. 284:33466 -33474.
14. Thomssen R, Bonk S, Propfe C, Heermann KH, Köchel HG, Uy A. 1992. Association of hepatitisCvirus in human sera with beta-lipoprotein. Med. Microbiol. Immunol. 181:293-300.
15. André P, Komurian-Pradel F, Deforges S, Perret M, Berland JL, Sodoyer M, Pol S, Bréchot C, Paranhos-Baccalà G, Lotteau V. 2002. Characterization of low- and very-low-density hepatitis C virus RNAcontaining particles. J. Virol. 76:6919-6928.
16. Nielsen SU, Bassendine MF, Burt AD, Martin C, Pumeechockchai W, Toms GL. 2006. Association between hepatitis C virus and very-lowdensity lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. J. Virol. 80:2418 -2428.
17. Felmlee DJ, Sheridan DA, Bridge SH, Nielsen SU, Milne RW, Packard CJ, Caslake MJ, McLauchlan J, Toms GL, Neely RDG, Bassendine MF. 2010. Intravascular transfer contributes to postprandial increase in numbers of very-low-density hepatitis C virus particles. Gastroenterology 139: 1774-1783.
18. Bartenschlager R, Penin F, Lohmann V, André P. 2011. Assembly of infectious hepatitis C virus particles. Trends Microbiol. 19:95-103.
19. Herker E, Ott M. 2011. Unique ties between hepatitis C virus replication and intracellular lipids. Trends Endocrinol. Metab. 22:241-248.
20. Lindenbach BD, Evans MJ, Syder AJ, Wölk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM. 2005. Complete replication of hepatitis C virus in cell culture. Science 309:623- 626.
21. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Kräusslich H.-G, Mizokami M, Bartenschlager R, Liang TJ. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11:791-796.
22. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, Wieland SF, Uprichard SL, Wakita T, Chisari FV. 2005. Robust hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. U. S. A. 102:9294 -9299.
23. Pietschmann T, Kaul A, Koutsoudakis G, Shavinskaya A, Kallis S, Steinmann E, Abid K, Negro F, Dreux M, Cosset F.-L, Bartenschlager R. 2006. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc. Natl. Acad. Sci. U. S. A. 103:7408 -7413.
24. Chang K.-S, Jiang J, Cai Z, Luo G. 2007. Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture. J. Virol. 81:13783-13793.
25. Cun W, Jiang J, Luo G. 2010. The C-terminal alpha-helix domain of apolipoprotein E is required for interaction with nonstructural protein 5A and assembly of hepatitis C virus. J. Virol. 84:11532-11541.
26. Hishiki T, Shimizu Y, Tobita R, Sugiyama K, Ogawa K, Funami K, Ohsaki Y, Fujimoto T, Takaku H, Wakita T, Baumert TF, Miyanari Y, Shimotohno K. 2010. Infectivity of hepatitis C virus is influenced by association with apolipoprotein E isoforms. J. Virol. 84:12048 -12057.
27. Jiang J, Luo G. 2009. Apolipoprotein E but not B is required for the formation of infectious hepatitis C virus particles. J. Virol. 83:12680- 12691.
28. Merz A, Long G, Hiet M.-S, Brügger B, Chlanda P, Andre P, Wieland F, Krijnse-locker J, Bartenschlager R. 2011. Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome. J. Biol. Chem. 286:3018 -3032.
29. Owen DM, Huang H, Ye J, Gale M. 2009. Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor. Virology 394:99 -108.
30. Lindenbach BD, Meuleman P, Ploss A, Vanwolleghem T, Syder AJ, McKeating JA, Lanford RE, Feinstone SM, Major ME, Leroux-Roels G, Rice CM. 2006. Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc. Natl. Acad. Sci. U. S. A. 103:3805- 3809.
31. Icard V, Diaz O, Scholtes C, Perrin-Cocon L, Ramière C, Bartenschlager R, Penin F, Lotteau V, André P. 2009. Secretion of hepatitis C virus envelope glycoproteins depends on assembly of apolipoprotein B positive lipoproteins. PLoS One 4:e4233. doi:10.1371/journal.pone .0004233.
32. Meex SJR, Andreo U, Sparks JD, Fisher EA. 2011. Huh-7 or HepG2 cells: which is the better model for studying human apolipoprotein-B100 assembly and secretion? J. Lipid Res. 52:152-158.
33. Dixon JL, Ginsberg HN. 1993. Regulation of hepatic secretion of apolipoprotein B-containing lipoproteins: information obtained from cultured liver cells. J. Lipid Res. 34:167-179.
34. Tsai J, Qiu W, Kohen-Avramoglu R, Adeli K. 2007. MEK-ERK inhibition corrects the defect in VLDL assembly in HepG2 cells: potential role of ERK in VLDL-ApoB100 particle assembly. Arterioscler. Thromb. Vasc. Biol. 27:211-218.
35. Bartosch B, Vitelli A, Granier C, Goujon C, Dubuisson J, Pascale S, Scarselli E, Cortese R, Nicosia A, Cosset F.-L. 2003. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J. Biol. Chem. 278:41624-41630.
36. Fukuhara T, Tani H, Shiokawa M, Goto Y, Abe T, Taketomi A, Shirabe K, Maehara Y, Matsuura Y. 2011. Intracellular delivery of serum-derived hepatitis C virus. Microbes Infect. 13:405- 412.
37. Harris HJ, Davis C, Mullins JGL, Hu K, Goodall M, Farquhar MJ, Mee CJ, McCaffrey K, Young S, Drummer H, Balfe P, McKeating JA. 2010. Claudin association with CD81 defines hepatitis C virus entry. J. Biol. Chem. 285:21092-21102.
38. Lupberger J, Zeisel MB, Xiao F, Thumann C, Fofana I, Zona L, Davis C, Mee CJ, Turek M, Gorke S, Royer C, Fischer B, Zahid MN, Lavillette D, Fresquet J, Cosset F.-L, Rothenberg SM, Pietschmann T, Patel AH, Pessaux P, Doffoël M, Raffelsberger W, Poch O, McKeating JA, Brino L, Baumert TF. 2011. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat. Med. 17:589- 595.
39. Sainz B, Jr, Barretto N, Yu X, Corcoran P, Uprichard SL. 2012. Permissiveness of human hepatoma cell lines for HCV infection. Virol. J. 9:30.
40. Date T, Kato T, Miyamoto M, Zhao Z, Yasui K, Mizokami M, Wakita T. 2004. Genotype 2a hepatitis C virus subgenomic replicon can replicate in HepG2 and IMY-N9 cells. J. Biol. Chem. 279:22371-22376.
41. Narbus CM, Israelow B, Sourisseau M, Michta ML, Hopcraft SE, Zeiner GM, Evans MJ. 2011. HepG2 cells expressing microRNA miR-122 support the entire hepatitis C virus life cycle. J. Virol. 85:12087-12092.
42. Mee CJ, Farquhar MJ, Harris HJ, Hu K, Ramma W, Ahmed A, Maurel P, Bicknell R, Balfe P, McKeating JA. 2010. Hepatitis C virus infection reduces hepatocellular polarity in a vascular endothelial growth factordependent manner. Gastroenterology 138:1134 -1142.
43. Mee CJ, Harris HJ, Farquhar MJ, Wilson G, Reynolds G, Davis C, van IJzendoorn SCD, Balfe P, McKeating JA. 2009. Polarization restricts hepatitisCvirus entry into HepG2 hepatoma cells. J. Virol. 83:6211- 6221.
44. Lim SP, Soo HM, Tan YH, Brenner S, Horstmann H, MacKenzie JM, Ng ML, Lim S.G., and Wjin Hong. 2002. Inducible system in human hepatoma cell lines for hepatitis C virus production. Virology 303:79 -99.
45. Dash S, Halim AB, Tsuji H, Hiramatsu N, Gerber MA. 1997. Transfection of HepG2 cells with infectious hepatitis C virus genome. Am. J. Pathol. 151:363-373.
46. McCormick CJ, Challinor L, Macdonald A, Rowlands DJ, Harris M. 2004. Introduction of replication-competent hepatitis C virus transcripts using a tetracycline-regulable baculovirus delivery system. J. Gen. Virol. 85:429-439.
47. el-Awady MK, Tabll AA, el-Abd YS, Bahgat MM, Shoeb HA, Youssef SS, Bader el-Din NG, Redwan el-RM, el-Demellawy M, Omran MH, el-Garf WT, Goueli SA. 2006. HepG2 cells support viral replication and gene expression of hepatitis C virus genotype 4 in vitro. World J. Gastroenterol. 12:4836-4842.
48. Owsianka A, Clayton RF, Loomis-Price LD, McKeating JA, Patel AH. 2001. Functional analysis of hepatitis C virus E2 glycoproteins and viruslike particles reveals structural dissimilarities between different forms of E2. J. Gen. Virol. 82:1877-1883.
49. Hadlock KG, Lanford RE, Perkins S, Rowe J, Yang Q, Levy S, Pileri P, Abrignani S, Foung SK. 2000. Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes. J. Virol. 74:10407-10416.
50. Delgrange D, Pillez A, Castelain S, Cocquerel L, Rouillé Y, Dubuisson J, Wakita T, Duverlie G, Wychowski C. 2007. Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins. J. Gen. Virol. 88:2495-2503.
51. Moradpour D, Evans MJ, Gosert R, Yuan Z, Blum HE, Goff SP, Lindenbach BD, Rice CM. 2004. Insertion of green fluorescent protein into nonstructural protein 5A allows direct visualization of functional hepatitis C virus replication complexes. J. Virol. 78:7400 -7409.
52. Blight KJ, McKeating JA, Rice CM. 2002. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J. Virol. 76: 13001-13014.
53. Bartosch B, Cosset F.-L. 2009. Studying HCV cell entry with HCV pseudoparticles (HCVpp). Methods Mol. Biol. 510:279 -293.
54. Lin R, Heylbroeck C, Pitha PM, Hiscott J. 1998. Virus-dependent phosphorylation of the IRF-3 transcription factor regulates nuclear translocation, transactivation potential, and proteasome-mediated degradation. Mol. Cell. Biol. 18:2986 -2996.
55. Komurian-Pradel F, Paranhos-Baccalà G, Sodoyer M, Chevallier P, Mandrand B, Lotteau V, André P. 2001. Quantitation of HCV RNA using real-time PCR and fluorimetry. J. Virol. Methods 95:111-119.
56. Sambrook J, Russell DW. 2001. Molecular cloning: a laboratory manual, 3rd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
57. Galbraith RA, Sassa S, Fujita H. 1988. Regulation of heme synthesis in HepG2 human hepatoma cells by dimethyl sulfoxide. Biochem. Biophys. Res. Commun. 153:869-874.
58. Sainz B, Chisari FV. 2006. Production of infectious hepatitis C virus by well-differentiated, growth-arrested human hepatoma-derived cells. J. Virol. 80:10253-10257.
59. Appel N, Zayas M, Miller S, Krijnse-locker J, Schaller T, Friebe P, Kallis S, Engel U, Bartenschlager R. 2008. Essential role of domain III of nonstructural protein 5A for hepatitisCvirus infectious particle assembly. PLoS Pathog. 4:e1000035. doi:10.1371/journal.ppat.1000035.
60. Lucifora J, Durantel D, Testoni B, Hantz O, Levrero M, Zoulim F. 2010. Control of hepatitis B virus replication by innate response of HepaRG cells. Hepatology 51:63-72.
61. Marion M.-J, Hantz O, Durantel D. 2010. The HepaRG cell line: biological properties and relevance as a tool for cell biology, drug metabolism, and virology studies. Methods Mol. Biol. 640:261-272.
62. Parent R, Marion M.-J, Furio L, Trépo C, Petit M.-A. 2004. Origin and characterization of a human bipotent liver progenitor cell line. Gastroenterology 126:1147-1156.
63. Sumpter R, Jr, Loo Y-M, Foy E, Li K, Yoneyama M, Fujita T, Lemon SM, Gale Jr, M. 2005. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J. Virol. 79:2689 -2699.
64. Chang K-O, George DW. 2007. Bile acids promote the expression of hepatitis C virus in replicon-harboring cells. J. Virol. 81:9633-9640.
65. Zhang T, Li Y, Lai J-P, Douglas SD, Metzger DS, O'Brien CP, Ho W.-Z. 2003. Alcohol potentiates hepatitis C virus replicon expression. Hepatology 38:57- 65.
66. Ndjomou J, Park I.-W, Liu Y, Mayo LD, He JJ. 2009. Up-Regulation of Hepatitis C Virus Replication and Production by Inhibition of MEK/ERK Signaling. PLoS One 4:e7498. doi:10.1371/journal.pone.0007498.
67. Milne RW, Theolis R, Jr, Verdery RB, Marcel YL. 1983. Characterization of monoclonal antibodies against human low density lipoprotein. Arteriosclerosis. 3:23-30.
68. Soler-lópez M, Zanzoni A, Lluís R, Stelzl U, Aloy P. 2011. Interactome mapping suggests new mechanistic details underlying Alzheimer's disease. Genome Res. 21:364 -376.
69. Lavillette D, Tarr AW, Voisset C, Donot P, Bartosch B, Bain C, Patel AH, Dubuisson J, Ball JK, Cosset F.-L. 2005. Characterization of hostrange and cell entry properties of the major genotypes and subtypes of hepatitis C virus. Hepatology 41:265-274.
70. Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R, Tschopp J. 2005. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437:1167- 1172.
71. Henke JI, Goergen D, Zheng J, Song Y, Schüttler CG, Fehr C, Jünemann C, Niepmann M. 2008. microRNA-122 stimulates translation of hepatitis C virus RNA. EMBO J. 27:3300 -3310.
72. Kambara H, Fukuhara T, Shiokawa M, Ono C, Ohara Y, Kamitani W, Matsuura Y. 2012. Establishment of a novel permissive cell line for the propagation of hepatitis C Virus by expression of microRNA miR122. J. Virol. 86:1382-1393.
73. Lin L-T, Noyce RS, Pham TNQ, Wilson JA, Sisson GR, Michalak TI, Mossman KL, Richardson CD. 2010. Replication of Subgenomic Hepatitis C virus replicons in mouse fibroblasts is facilitated by deletion of interferon regulatory factor 3 and expression of liver-specific microRNA 122. J. Virol. 84:9170 -9180.
74. van IJzendoorn SC, Hoekstra D. 2000. Polarized sphingolipid transport from the subapical compartment changes during cell polarity development. Mol. Biol. Cell 11:1093-1101.
75. Zegers MM, Hoekstra D. 1998. Mechanisms and functional features of polarized membrane traffic in epithelial and hepatic cells. Biochem. J. 336:257-269.
76. Whittaker S, Marais R, Zhu AX. 2010. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 29:4989 -5005.
77. Benga WJA, Krieger SE, Dimitrova M, Zeisel MB, Parnot M, Lupberger J, Hildt E, Luo G, McLauchlan J, Baumert TF, Schuster C. 2010. Apolipoprotein E interacts with hepatitisCvirus nonstructural protein 5A and determines assembly of infectious particles. Hepatology 51:43-53.
78. Liu S, McCormick KD, Zhao W, Zhao T, Fan D, Wang T. 2012. Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding. Hepatology 56:484-491.
79. Gastaminza P, Cheng G, Wieland S, Zhong J, Liao W, Chisari FV. 2008. Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. J. Virol. 82:2120 -2129.
80. Huang H, Sun F, Owen DM, Li W, Chen Y, Gale M, Ye J. 2007. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc. Natl. Acad. Sci. U. S. A. 104:5848 -5853.
81. Nahmias Y, Goldwasser J, Casali M, van Poll D, Wakita T, Chung RT, Yarmush ML. 2008. Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin. Hepatology 47: 1437-1445.
82. Akazawa D, Morikawa K, Omi N, Takahashi H, Nakamura N, Mochizuki H, Date T, Ishii K, Suzuki T, Wakita T. 2011. Production and characterization of HCV particles from serum-free culture. Vaccine 29: 4821-4828.
83. Saito H, Dhanasekaran P, Baldwin F, Weisgraber KH, Lund-katz S, Phillips MC. 2001. Lipid binding-induced conformational change in human apolipoprotein E. Evidence for two lipid-bound states on spherical particles. J. Biol. Chem. 276:40949-40954.
84. Gastaminza P, Kapadia SB, Chisari FV. 2006. Differential biophysical properties of infectious intracellular and secreted hepatitis C virus particles. J. Virol. 80:11074 -11081.
85. Scholtes C, Ramière C, Rainteau D, Perrin-Cocon L, Wolf C, Humbert L, Carreras M, Guironnet-Paquet A, Zoulim F, Bartenschlager R, Lotteau V, André P, Diaz O. 2012. High plasma level of nucleocapsid-free envelope glycoprotein-positive lipoproteins in hepatitis C patients. Hepatology 56:39-48.